Please assess the completion status of the following clinical trial:

Trial Title: Asymptomatic Congenital CMV Treatment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Parent(s)/legal guardian(s) have signed informed consent documents\*~* Confirmation of cytomegalovirus (CMV) by urine polymerase chain reaction (PCR) testing~* Infant \</= 30 days of age at initiation of study drug~* Weight at study enrollment \>/= 1775 grams~* Gestational age \>/= 32 weeks at birth~  * There is a screening informed consent for screening phase of study participation, and a treatment informed consent for treatment phase of study participation.~Exclusion Criteria:~* Symptomatic congenital cytomegalovirus (CMV) disease\*~* Sensorineural hearing deficits as detected by formal brainstem evoked response (not a screening auditory brainstem response (abr)) of known etiology other than CMV~* Prior or current receipt of ganciclovir, valganciclovir, foscarnet, cidofovir, brincidofovir, maribavir, or letermovir~* Maternal receipt of CMV hyperimmune globulin during pregnancy~* Breastfeeding from mother who is receiving ganciclovir, valganciclovir, foscarnet, cidofovir, brincidofovir, maribavir, or letermovir~* Gastrointestinal abnormality which might preclude absorption of an oral medication (e.g., a history of necrotizing enterocolitis)~* Infants known to be born to women who are HIV positive (HIV testing is not required for study entry)~* Current receipt of other investigational drugs~  * Symptomatic disease is defined as one or more of the following: 1) thrombocytopenia, if known; 2) petechiae; 3) hepatomegaly; 4) splenomegaly; 5) intrauterine growth restriction; 6) hepatitis (elevated transaminases and/or direct bilirubin), if known; 7) central nervous system involvement of the CMV disease (such as microcephaly; radiographic abnormalities indicative of CMV CNS disease, if known; abnormal CSF indices for age, if known; chorioretinitis, if known; and/or positive CMV PCR from CSF, if known).

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 30 Days
- Healthy Volunteers: f

Study Arms:
- Confirmed congenital CMV without baseline SNHL (Type: EXPERIMENTAL): Valganciclovir 16 mg/kg/dose orally twice daily for four months, n=229

Based on this trial design, predict the completion outcome and termination type (if applicable).